ACUTE MYELOID LEUKEMIA RECURRENT
Clinical trials for ACUTE MYELOID LEUKEMIA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA RECURRENT trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cell boost shows promise in early leukemia trial
Disease control Recruiting nowThis early-phase study tests the safety of giving special immune cells (CIML NK cells) along with a standard drug (venetoclax) to adults with acute myeloid leukemia (AML) whose disease has come back or is hard to treat. Ten participants will receive the cell infusion after a shor…
Matched conditions: ACUTE MYELOID LEUKEMIA RECURRENT
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New drug combo shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage study tests whether adding the experimental drug ziftomenib to standard AML treatments is safe and effective. About 420 adults with specific genetic mutations (NPM1 or KMT2A) will receive one of three drug combinations. The goal is to find the best dose and see i…
Matched conditions: ACUTE MYELOID LEUKEMIA RECURRENT
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC